PT  - JOURNAL ARTICLE
AU  - GUTHRIE, MARGARET L.
AU  - SIDHU, PREETPAL S.
AU  - HILL, EMILY K.
AU  - HORAN, TIMOTHY C.
AU  - NANDHIKONDA, PREMCHENDAR
AU  - TESKE, KELLY A.
AU  - YUAN, NINA Y.
AU  - SIDORKO, MARINA
AU  - RODALI, REVATHI
AU  - COOK, JAMES M.
AU  - HAN, LANLAN
AU  - SILVAGGI, NICHOLAS R.
AU  - BIKLE, DANIEL D.
AU  - MOORE, RICHARD G.
AU  - SINGH, RAKESH K.
AU  - ARNOLD, LEGGY A.
TI  - Antitumor Activity of 3-Indolylmethanamines 31B and PS121912
DP  - 2015 Nov 01
TA  - Anticancer Research
PG  - 6001--6007
VI  - 35
IP  - 11
4099  - http://ar.iiarjournals.org/content/35/11/6001.short
4100  - http://ar.iiarjournals.org/content/35/11/6001.full
SO  - Anticancer Res2015 Nov 01; 35
AB  - Aim: To investigate the in vivo effects of 3-indolylmethanamines 31B and PS121912 in treating ovarian cancer and leukemia, respectively. Materials and Methods: Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) and western blotting were applied to demonstrate the induction of apoptosis. Xenografted mice were investigated to show the antitumor effects of 3-indolylmethanamines. 13C-Nuclear magnetic resource (NMR) and western blotting were used to demonstrate inhibition of glucose metabolism. Results: 31B inhibited ovarian cancer cell proliferation and activated caspase-3, cleaved poly (ADP-ribose) polymerase 1 (PARP1), and phosphorylated mitogen-activated protein kinases (MAPK), JUN N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38. 31B reduced ovarian cancer xenograft tumor growth and PS121912 inhibited the growth of HL-60-derived xenografts without any sign of toxicity. Compound 31B inhibited de novo glycolysis and lipogenesis mediated by the reduction of fatty acid synthase and lactate dehydrogenase-A expression. Conclusion: 3-Indolylmethanamines represent a new class of antitumor agents. We have shown for the first time the in vivo anticancer effects of 3-indolylmethanamines 31B and PS121912.